X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GLENMARK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GLENMARK PHARMA LUPIN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 16.5 13.7 120.0% View Chart
P/BV x 3.8 3.8 99.8% View Chart
Dividend Yield % 0.8 0.3 243.0%  

Financials

 LUPIN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
GLENMARK PHARMA
Mar-16
LUPIN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,1271,262 168.5%   
Low Rs1,294672 192.7%   
Sales per share (Unadj.) Rs304.1270.6 112.4%  
Earnings per share (Unadj.) Rs50.424.9 202.6%  
Cash flow per share (Unadj.) Rs60.734.4 176.3%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.40.2 211.9%  
Book value per share (Unadj.) Rs243.8151.3 161.1%  
Shares outstanding (eoy) m450.58282.16 159.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.63.6 157.4%   
Avg P/E ratio x33.938.9 87.3%  
P/CF ratio (eoy) x28.228.1 100.3%  
Price / Book Value ratio x7.06.4 109.8%  
Dividend payout %14.98.0 185.1%   
Avg Mkt Cap Rs m770,740272,778 282.6%   
No. of employees `00016.410.0 163.1%   
Total wages/salary Rs m21,07713,782 152.9%   
Avg. sales/employee Rs Th8,379.67,614.9 110.0%   
Avg. wages/employee Rs Th1,289.01,374.8 93.8%   
Avg. net profit/employee Rs Th1,388.7700.2 198.3%   
INCOME DATA
Net Sales Rs m137,01676,340 179.5%  
Other income Rs m1,877356 526.9%   
Total revenues Rs m138,89376,696 181.1%   
Gross profit Rs m37,53514,172 264.9%  
Depreciation Rs m4,6352,691 172.2%   
Interest Rs m4461,789 24.9%   
Profit before tax Rs m34,33010,048 341.7%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,5363,028 380.9%   
Profit after tax Rs m22,7077,019 323.5%  
Gross profit margin %27.418.6 147.6%  
Effective tax rate %33.630.1 111.5%   
Net profit margin %16.69.2 180.2%  
BALANCE SHEET DATA
Current assets Rs m97,79059,096 165.5%   
Current liabilities Rs m53,87240,018 134.6%   
Net working cap to sales %32.125.0 128.3%  
Current ratio x1.81.5 122.9%  
Inventory Days Days8575 113.0%  
Debtors Days Days121119 101.7%  
Net fixed assets Rs m86,37939,075 221.1%   
Share capital Rs m901282 319.3%   
"Free" reserves Rs m105,73530,281 349.2%   
Net worth Rs m109,84442,703 257.2%   
Long term debt Rs m53,73924,873 216.1%   
Total assets Rs m224,378111,026 202.1%  
Interest coverage x77.96.6 1,177.9%   
Debt to equity ratio x0.50.6 84.0%  
Sales to assets ratio x0.60.7 88.8%   
Return on assets %10.37.9 130.1%  
Return on equity %20.716.4 125.8%  
Return on capital %21.217.5 121.1%  
Exports to sales %49.143.3 113.4%   
Imports to sales %7.47.4 100.2%   
Exports (fob) Rs m67,24433,044 203.5%   
Imports (cif) Rs m10,1995,672 179.8%   
Fx inflow Rs m71,40536,945 193.3%   
Fx outflow Rs m17,80761,066 29.2%   
Net fx Rs m53,598-24,122 -222.2%   
CASH FLOW
From Operations Rs m-3,6903,449 -107.0%  
From Investments Rs m-69,434-8,802 788.9%  
From Financial Activity Rs m58,1266,986 832.0%  
Net Cashflow Rs m-14,998934 -1,606.1%  

Share Holding

Indian Promoters % 46.6 48.3 96.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 31.9 34.4 92.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 56,727 173.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Down 4.1%(09:30 am)

Asian stock markets opened mixed in early trade today. Hong Kong Hang Seng has advanced 143 points and China's Shanghai Composite has gained 9 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 21, 2017 10:13 AM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - ELDER PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS